Osteoarthritis of the hip
Conditions
Interventions
Intraarticular injection of Hylan G-F 20 for osteoarthritis of the hip
Sponsors
Department of Orthopaedic Surgery, Tokyo Medical and Dental University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients meeting all following (1)-(4) at registration are adopted. (1) Patients diagnosed OA of hip joint. (2) Outpatients who can walk. (3) Patients aged 20-84 years. (4) Patients who submitted the consent of this study before the registration by understanding the method.
Exclusion criteria
Exclusion criteria: Exclusion criteria of the patients are as follows. (1) Patients lacking ability to agree or ability to express agreement for participation appropriately in this study. (2) Pregnancy or its possibility. (3) Patients suckling child. (4) Patients with hypersensitivity for the ingredient of this medicine, hyaluronic acid, avian protein, feather, or egg. (5) Patients with stagnation of venous blood or lymph fluid in lower limbs on injection side. (6) Patients with a serious liver damage or its medical history. (7) Patients with skin disease or with infection on the injection part. (8) Patients with serious complications (heart disorder, renal disease, a malignant tumor, or compromised host such as immunodeficiency). (9) Patients judged inadequate by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physical findings and patient-based subjective assessment right after, 4, 8, and 12 weeks after intra-articular injection of hyaluronic acid | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events | — |
Countries
Japan
Contacts
Public ContactGaku Koyano
Tokyo Medical and Dental University Department of Orthopaedic Surgery
Outcome results
None listed